0001708527
false
0001708527
2023-07-13
2023-07-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): July 13, 2023
AZIYO BIOLOGICS, INC.
(Exact name of registrant as specified in its
charter)
Delaware |
|
001-39577 |
|
47-4790334 |
(State
or other jurisdiction of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
12510
Prosperity Drive, Suite 370,
Silver Spring, MD
20904
(Address
of principal executive offices) (Zip Code)
(240)
247-1170
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Class A
Common Stock, $0.001 par value per share |
|
AZYO |
|
The Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 7.01. Regulation FD Disclosure.
On July 13, 2023, Aziyo Biologics, Inc.
(the “Company” or “Aziyo”) issued a press release announcing the events described in Item 8.01 of this Current
Report on Form 8-K (“Form 8-K”). A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K
and is incorporated herein by reference.
The information contained in this Item 7.01 (including
Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed
to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except
as expressly set forth by specific reference in such filing.
Item 8.01. Other Events.
On July 13, 2023, the Company announced the voluntary
recall of its viable bone matrix products, which are bone repair products made from human tissue that are used primarily in orthopedic
and spinal procedures.
Notice of the voluntary recall was issued to centers
after the Company learned of post-surgical Mycobacterium tuberculosis (“MTB”) infections in two patients treated with viable
bone matrix product from a single donor lot. Prior to release, samples from this specific lot had tested negative for MTB by an independent laboratory
using a nucleic acid test that is designed to specifically detect the MTB organism. Aziyo is investigating the source of the infections
in coordination with the U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention (“CDC”).
Out of an abundance of caution, the Company has
suspended shipments of all viable bone matrix products from all donor lots. The Company is also working closely with CDC staff to notify
physicians of the patients who received the particular donor lot at issue to initiate post-exposure prophylaxis.
Forward-Looking Statements
This current report on Form 8-K contains “forward-looking
statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as “projects,” “may,”
“will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,”
“estimates,” “intends,” “plans,” “potential,” “promise” or similar references
to future periods. All statements contained in this press release that do not relate to matters of historical fact should be considered
forward-looking statements, including statements and information concerning the suspension of sales of the Company’s viable bone
matrix products, and any impact of the recall and suspension of sales of these products on the Company’s business. Forward-looking
statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect
our business, strategy, operations or financial performance, and actual results may differ materially from those expressed or implied
in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties,
some of which cannot be predicted or quantified, and other important factors that may cause actual results, performance or achievements
to differ materially from those contemplated or implied in this Form 8-K, including, but not limited to: the technical complexity
and requisite high levels of quality control and precision in processing of tissue needed for the Company’s products, including
its viable bone matrix; defects, failures or quality issues associated with the Company’s products that lead to product recalls
or safety alerts, adverse regulatory actions, litigation, including product liability claims, and negative publicity; sufficient insurance
coverage and reimbursement for procedures incorporating the Company’s products; product liability claims, including those that may
arise from the recall of its viable bone matrix, for which the Company may not receive adequate, if any, product liability coverage; the
Company’s risk exposure from warranty claims on its products; our inability to generate sufficient revenue to achieve or sustain
profitability; adverse changes in economic conditions and instability and disruption of credit markets; our ability to continue as a going
concern; our products and our ability to enhance, expand, develop and commercialize our product offerings; our dependence on our commercial
partners; physician awareness of the distinctive characteristics, and acceptance by the medical community, of our products; the ability
to obtain regulatory approval or other marketing authorizations; our intellectual property rights; and other important factors which can
be found in the “Risk Factors” section of Aziyo’s public filings with the Securities and Exchange Commission (“SEC”),
including Aziyo’s Annual Report on Form 10-K for the year ended December 31, 2022, as such factors may be updated from
time to time in Aziyo’s other filings with the SEC, including, Aziyo’s Quarterly Reports on Form 10-Q, accessible on
the SEC’s website at www.sec.gov and the Investor Relations page of Aziyo’s website at https://investors.aziyo.com. Because
forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements
as predictions of future events. Any forward-looking statement made by Aziyo in this press release is based only on information currently
available and speaks only as of the date on which it is made. Except as required by applicable law, Aziyo expressly disclaims any obligations
to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of
new information, future developments or otherwise.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
AZIYO BIOLOGICS, INC. |
|
(Registrant) |
|
|
Date: July 13, 2023 |
By: |
/s/ Matthew Ferguson |
|
Matthew Ferguson |
|
Chief Financial Officer |
Exhibit 99.1
Aziyo Biologics Announces
Voluntary Recall of Viable Bone Matrix Products
SILVER SPRING, Md., July 13, 2023 —
Aziyo Biologics, Inc. (Nasdaq: AZYO), a company that develops and commercializes biologic products to improve compatibility between medical
devices and the patients who need them, today announced a voluntary recall of its viable bone matrix products, which are bone repair
products made from human tissue that are used primarily in orthopedic and spinal procedures.
Notice of the voluntary recall was issued
to centers after the Company learned of post-surgical Mycobacterium tuberculosis (MTB) infections in two patients treated with
viable bone matrix product from a single donor lot. Prior to release, samples from this specific lot had tested negative for MTB by an
independent laboratory using a nucleic acid test that is designed to specifically detect the MTB organism. Aziyo is fully cooperating
and investigating the events in coordination with the U.S. Food and Drug Administration and the U.S. Centers for Disease Control and
Prevention (CDC).
Out of an abundance of caution, the Company
has suspended shipments of all viable bone matrix products from all donor lots. The Company is also working closely with CDC staff to
notify physicians of the patients who received the particular donor lot at issue to initiate post-exposure prophylaxis.
“We are taking immediate action to
safeguard patients by implementing a full product recall as we work with the CDC to investigate this event,” said Dr. Randy Mills,
President and Chief Executive Officer of Aziyo Biologics. “The people of Aziyo care deeply about the patients we serve and will
continue to work with the medical community, patients, and regulatory authorities as we gather additional information.”
About Aziyo Biologics
Aziyo develops and commercializes
biologic products to improve compatibility between medical devices and the patients who need them. With a growing population in need
of implantable technologies, Aziyo’s mission is to humanize medical
devices to improve patient outcomes. For more information, visit www.Aziyo.com.
Forward-Looking Statements
This press release contains “forward-looking
statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended. Forward-looking statements can be identified by words such as “projects,”
“may,” “will,” “could,” “would,” “should,” “believes,” “expects,”
“anticipates,” “estimates,” “intends,” “plans,” “potential,” “promise”
or similar references to future periods. All statements contained in this press release that do not relate to matters of historical fact
should be considered forward-looking statements, including statements and information concerning the suspension of sales of the Company’s
viable bone matrix products, and any impact of the recall and suspension of sales of these products on the Company’s
business. Forward-looking statements are based on management’s
current assumptions and expectations of future events and trends, which affect or may affect our business, strategy, operations or financial
performance, and actual results may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties.
Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and other
important factors that may cause actual results, performance or achievements to differ materially from those contemplated or implied
in this press release, including, but not limited to, risks regarding the technical complexity and requisite high levels of quality control
and precision in processing of tissue needed for the Company’s
products, including viable bone matrix; defects, failures or quality issues associated with the Company’s
products that lead to product recalls or safety alerts, adverse regulatory actions, litigation, including product liability claims, and
negative publicity; sufficient insurance coverage and reimbursement for procedures incorporating the Company’s
products; product liability claims, including those that may arise from the recall of viable bone matrix, for which the Company may not
receive adequate, if any, product liability coverage; the Company’s
risk exposure from warranty claims on its products; our inability to generate sufficient revenue to achieve or sustain profitability;
adverse changes in economic conditions and instability and disruption of credit markets; our ability to continue as a going concern;
our products and our ability to enhance, expand, develop and commercialize our product offerings; our dependence on our commercial partners;
physician awareness of the distinctive characteristics, and acceptance by the medical community, of our products; the ability to obtain
regulatory approval or other marketing authorizations; our intellectual property rights; and other important factors which can be found
in the “Risk Factors” section of Aziyo’s
public filings with the Securities and Exchange Commission (“SEC”),
including Aziyo’s Annual Report on Form 10-K for the year ended
December 31, 2022, as such factors may be updated from time to time in Aziyo’s
other filings with the SEC, including, Aziyo’s Quarterly Reports
on Form 10-Q, accessible on the SEC’s website at www.sec.gov and
the Investor Relations page of Aziyo’s website at https://investors.aziyo.com.
Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements
as predictions of future events. Any forward-looking statement made by Aziyo in this press release is based only on information currently
available and speaks only as of the date on which it is made. Except as required by applicable law, Aziyo expressly disclaims any obligations
to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of
new information, future developments or otherwise.
Contact:
Matt Steinberg
FINN Partners
matt.steinberg@finnpartners.com
v3.23.2
Cover
|
Jul. 13, 2023 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Jul. 13, 2023
|
Entity File Number |
001-39577
|
Entity Registrant Name |
AZIYO BIOLOGICS, INC.
|
Entity Central Index Key |
0001708527
|
Entity Tax Identification Number |
47-4790334
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
12510
Prosperity Drive
|
Entity Address, Address Line Two |
Suite 370
|
Entity Address, City or Town |
Silver Spring
|
Entity Address, State or Province |
MD
|
Entity Address, Postal Zip Code |
20904
|
City Area Code |
240
|
Local Phone Number |
247-1170
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Class A
Common Stock, $0.001 par value per share
|
Trading Symbol |
AZYO
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Aziyo Biologics (NASDAQ:AZYO)
過去 株価チャート
から 4 2024 まで 5 2024
Aziyo Biologics (NASDAQ:AZYO)
過去 株価チャート
から 5 2023 まで 5 2024